Hørsholm, Denmark (PRWEB) December 10, 2012
Visiopharm, a leading provider of quantitative digital pathology solutions, has entered into a final agreement to acquire Digital Pathology Consultants, LLC based in Westminster, Colorado. The transaction is expected to be completed by the end of December. Amanda Lowe, founder of Digital Pathology Consultants, will join the management team as the Director of Marketing for Visiopharm in the Americas. Ms. Lowe has over 8 years experience in all aspects of Digital Pathology.
Michael Grunkin PhD, CEO of Visiopharm stated “Amanda Lowe is highly respected in this field and has been at the core of the Digital Pathology industry since its beginning. Her experience and holistic view of Digital Pathology will become an invaluable asset to our business partners and to our rapidly growing base of digital pathology adopters in the Americas.”
Ms. Lowe stated “I am extremely excited to join the very talented team at Visiopharm. Visiopharm’s solutions for quantitative digital pathology provide customers with cutting edge innovation that delivers superior results. I look forward to driving Visiopharm’s growth throughout the Americas.”
Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 300 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.
About Digital Pathology Consultants
Digital Pathology Consultants, a consultancy firm founded in 2009, was formed to advise current and potential digital pathology users within the healthcare, research, and biopharmaceutical markets on how to be productive and financially successful with digital pathology solutions. Digital Pathology Consultants also provided a large range of advisory services to the commercial digital pathology market including business development, strategic planning, and market research.